Kinarus Therapeutics Holding Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Alexander Bausch
Chief executive officer
CHF 291.4k
Total compensation
| CEO salary percentage | 51.8% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Alexander Bausch (61 yo)
1.8yrs
Tenure
CHF 291,381
Compensation
Dr. Alexander Bausch is Chief Executive Officer, Co-Founder and Director of Strekin AG from August 2014. Dr. Bausch is Chief Executive Officer of Kinarus Therapeutics Holding AG since June 02, 2022 and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.8yrs | CHF 291.38k | no data | |
| Chief Clinical Development Officer | 1.8yrs | CHF 136.73k | 0.67% CHF 25.9k | |
| Chief Medical Officer | 1.8yrs | CHF 136.73k | 0.21% CHF 8.2k | |
| COO & Head of Research | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
Experienced Management: KNRS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | 1.8yrs | no data | 4.18% CHF 160.9k |
0.3yrs
Average Tenure
Experienced Board: KNRS's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/25 06:18 |
| End of Day Share Price | 2024/04/25 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kinarus Therapeutics Holding AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Smith | Equity Development Limited |